Advertisement News Archives - Page 2876 of 5236 - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

September 11, 2026

Exegenesis Bio and Modalis sign research deal for Duchenne therapy

Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).

Exegenesis Bio and Modalis sign research deal for Duchenne therapy